<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00501332</url>
  </required_header>
  <id_info>
    <org_study_id>MP-CL-30166</org_study_id>
    <secondary_id>EUDRACT No.: 2006-006565-16</secondary_id>
    <secondary_id>PAREXEL 84728</secondary_id>
    <nct_id>NCT00501332</nct_id>
  </id_info>
  <brief_title>Evaluation of Maxy-G34 in Breast Cancer Patients Treated With TAC (Docetaxel, Adriamycin, Cyclophosphamide) Chemotherapy</brief_title>
  <official_title>A Phase IIa, Open Label, Controlled, Dose Ranging Study of Maxy-G34 as an Adjunct to TAC Chemotherapy in High-Risk Patients With Stage I, II, or IIIa Breast Cancer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maxygen Holdings Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Maxygen ApS</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Maxygen, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Parexel</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Maxygen Holdings Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an investigation of the safety and efficacy of Maxy-G34 in breast cancer patients
      treated with TAC chemotherapy. Maxy-G34 will be given as a single injection during each cycle
      of chemotherapy, for a planned total of six chemotherapy cycles.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2007</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the duration of grade 4 neutropenia after administration of Maxy-G34 in chemotherapy cycle 1.</measure>
    <time_frame>over 1 cycle of TAC chemotherapy (approximately 3 weeks)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine the duration of grade 4 neutropenia after administration of Maxy-G34 in chemotherapy cycles 2-6.</measure>
    <time_frame>over cycles 2-6 of TAC chemotherapy (approximately from weeks 4-18)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the incidence of grade 4 neutropenia after administration of each of the 6 doses of Maxy-G34.</measure>
    <time_frame>over all 6 cycles of TAC chemotherapy (approximately 18 weeks)</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Chemotherapy-Induced Neutropenia</condition>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Maxy-G34</intervention_name>
    <description>Maxy-G34 will be administered by subcutaneous injection during each of 6 TAC chemotherapy cycles.</description>
    <arm_group_label>2</arm_group_label>
    <other_name>pegylated recombinant human G-CSF</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          1. Males and females at least 18 years of age

          2. Diagnosis of high-risk stage I, II or IIIa breast cancer suitable for adjuvant TAC
             chemotherapy as based on investigator judgment

          3. Candidates for TAC chemotherapy, and no prior treatment with anthracyclines

        Key Exclusion Criteria:

          1. Received chemotherapy within last 3 month prior to screening, or expected to receive
             any chemotherapy other than TAC and / or immunotherapy between screening and 30 days
             after last planned study drug administration

          2. Any clinically significant findings on history or examination that, in the opinion of
             the investigator, would preclude administration of TAC chemotherapy in the full dose,
             including abnormal liver function, inadequate cardiac function or clinically
             significant cardiac disease, neuropathy or other disease

          3. Prior bone marrow or peripheral blood hematopoietic stem cell transplant

          4. Any active cancer or history of prior malignancy within the last 5 years except
             carcinoma in situ of the cervix, basal cell carcinoma or squamous cell carcinoma of
             the skin or any surgically cured malignancy diagnosed 5 years or more before diagnosis
             of breast cancer
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Santosh Vetticaden, MD</last_name>
    <role>Study Director</role>
    <affiliation>Maxygen, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Doris Apt</last_name>
    <phone>650-298-5367</phone>
    <email>Doris.Apt@maxygen.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Bydgoszcz</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Gdansk</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Lublin</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Alba-Iulia</city>
        <country>Romania</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Bucuresti</city>
        <country>Romania</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Jud. Bacau</city>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Suceava</city>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Timisoara</city>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Leningrad region</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Moscow Area</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Ryazan</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Dnipropetrovsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Uzhorod</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Poland</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Ukraine</country>
  </location_countries>
  <verification_date>December 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 12, 2007</study_first_submitted>
  <study_first_submitted_qc>July 12, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 16, 2007</study_first_posted>
  <last_update_submitted>December 19, 2007</last_update_submitted>
  <last_update_submitted_qc>December 19, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 24, 2007</last_update_posted>
  <responsible_party>
    <name_title>Santosh Vetticaden, MD. Chief Medical Officer.</name_title>
    <organization>Maxygen, Inc.</organization>
  </responsible_party>
  <keyword>neutropenia</keyword>
  <keyword>breast</keyword>
  <keyword>cancer</keyword>
  <keyword>chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Neutropenia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

